What's Happening?
Quiver Bioscience has received a multi-year grant from the National Institutes of Health (NIH) to advance its Nav1.7-targeted antisense oligonucleotide (ASO) therapy, QV-2421, through early clinical trials for chronic neuropathic pain. The grant, part
of the NIH's Helping to End Addiction Long-term (HEAL) Initiative, provides up to $9.3 million in direct funding and access to NIH-supported development resources. This funding will support key preclinical activities and an initial clinical trial, with total potential development support of approximately $20 million. QV-2421 targets the Nav1.7 sodium channel, a key mediator of pain transmission, aiming to provide sustained pain relief without the addiction risks associated with opioids. Quiver's approach leverages its Discovery Platform, which combines machine learning, optical electrophysiology, and patient-derived sensory neuron models, to optimize the therapy for clinical development.
Why It's Important?
The NIH grant represents a significant step forward in developing non-opioid therapies for chronic pain, a condition affecting millions globally. Current treatments often involve opioids, which carry risks of dependence and adverse effects. By targeting the Nav1.7 sodium channel, Quiver's ASO therapy could offer a more effective and safer alternative. The grant supports the advancement of a therapy that addresses a critical unmet need in pain management, potentially improving the quality of life for patients with chronic neuropathic pain. The success of this program could pave the way for similar approaches in treating other pain-related conditions, reducing reliance on opioids and contributing to efforts to combat the opioid crisis.
